Funding for two new medicines will provide patients with more convenient options for treating multiple sclerosis.
A new analysis of cancer medicine access in Australia and New Zealand shows that New Zealanders are getting access to the best cancer medicines available, says PHARMAC medical director Dr John Wyeth.
People with the rare blood condition hereditary angioedema are the first to benefit from the increased competition for rare disorders medicines promoted by PHARMAC.
PHARMAC’s annual tender continues to achieve its objectives, freeing up nearly $45 million from the 2014/15 tender round to reinvest in more medicines for more New Zealanders.
PHARMAC medical director Dr John Wyeth is welcoming the appointment of a new Chair and two new members to the Pharmacology and Therapeutics Advisory Committee (PTAC).
Wellington smoking cessation advocate Shane Bradbrook has been appointed chair of PHARMAC’s Consumer Advisory Committee.
In changes to take effect from 1 September, PHARMAC is moving to have a preferred brand of recombinant Factor VIII, while also maintaining full funding for the other three currently-funded haemophilia products.
PHARMAC is consulting on moving to the next stage in its hospital medical devices work – market share procurement.
PHARMAC will begin funding for the prostate cancer treatment abiraterone (Zytiga) from 1 May 2015, potentially benefiting up to 1000 men annually.
Estimated savings achieved through PHARMAC’s tender of off-patent medicines have now topped $600 million.
PHARMAC has secured the first national contract in the hospital medical device category for orthopaedic trauma, spine, and cranio-maxillofacial implants.
PHARMAC is in active negotiations with several suppliers as a result of its competitive process for rare disorders medicines.
We’re giving you the opportunity to tell us how we’re doing, what it’s like to work with us and what we can do better in a stakeholder survey.
Four Māori pharmacy students have been awarded Hiwinui Heke pharmacy scholarships – two each from the Auckland and Otago Schools of Pharmacy.
District Health Boards are poised to save more than $100 million over five years as a result of PHARMAC’s expanded role, PHARMAC reports in its Annual Review, released today.
A new agreement for a high cost biologic drug will yield considerable savings for DHBs over the next five years, says PHARMAC.
PHARMAC will change the way it makes funding decisions from late next year.
DHBs are expected to start making further savings in cardiac medical devices, after PHARMAC extended the range of products it already has under national contracts by beginning listing those used in cardiac procedures.
New Zealand hospitals are about to strengthen their defences against multi-resistant bacterial infections with the funding of a new antibiotic.
PHARMAC decisions to fund four new medicines will improve treatment options for over 10,000 people with a wide range of respiratory conditions.